Progyny director Kevin Gordon sells 5,500 shares in largest single transaction
SEC filings show director sold stock for $137,000 on 27 May 2026, retaining all indirect trust shares as the fertility benefits provider reports mixed first-quarter results.
Kevin K. Gordon, a director at Progyny, sold 5,500 shares of common stock for approximately $137,000 on 27 May 2026, according to Securities and Exchange Commission Form 4 filings. The transaction, executed at a weighted average price of $24.99 per share, represented 20.13 per cent of Gordon’s combined direct and indirect ownership immediately prior to the sale.
The disposition marks Gordon’s largest single sale to date. Since May of the previous year, he has executed two sales totaling 8,000 shares. The latest transaction reduced his direct holdings to less than one-quarter of the level held twelve months prior, although Gordon retained all 15,027 indirect shares, which remain held in the Kevin Gordon Revocable Declaration of Trust.
Progyny provides fertility and family-building benefits solutions, including plan design, concierge support, and integrated pharmacy benefits, primarily to large US employers. The company reported first-quarter revenue of $328 million, a 1.4 per cent year-on-year increase, with gross profit growing 10 per cent to $83.1 million. Client growth remained robust, with the client base expanding by 12 per cent year-on-year to 595 clients as of 31 March 2026.
Revenue growth was impacted by the loss of a large client, yet the company’s board recently approved a $200 million share repurchase program. Total revenue is expected to climb by 5.9 per cent to 9.0 per cent in 2026, driven by new clients and operational efficiency gains within the fertility benefits sector.
Gordon has served on Progyny’s board since 2019. The Motley Fool, which published the original report on the transaction, holds positions in and recommends Progyny. The source article was published by The Motley Fool, which has positions in and recommends Progyny.
